Investigation of the predictive roles of erythropoietin, ghrelin and biochemical parameters in patients with renal failure
Archives of Advances in Biosciences,
Vol. 16 No. 1 (2025),
2 Esfand 2025
,
Page 1-8
https://doi.org/10.22037/aab.v16i1.50536
Abstract
Introduction: kidney dysfunction is the loss of elimination of wastes of the kidneys in an adequate manner, which causes the accumulation of nitrogenous substances in the circulation. This condition is present in acute and chronic forms. The last stage renal disease (ESRD) is the terminus stage which requires renal replacement measures.
The purpose of the research was to examine how the erythropoietin and ghrelin hormones are expected to play and how the biochemical parameters play in clinical assessment of patients with renal failure.
Materials and Methods: The present study was undertaken using the sample of patients with renal failure undergoing dialysis at Baquba Teaching Hospital during the months of January to April 2022. The 62 and 35 were the patients who reported kidney failure and non-renal healthy controls, respectively. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) on serum samples were measured using the Cobas e411 analyzer. Nephric functional parameters (urea, uric acid and creatinine) were also measured on serum samples through the Cobas e411 analyzer. Ghrelin and erythropoietin hormone assays were done through the enzyme linked immunosorbent assay. The SPSS comprehension software was used to conduct the statistical analysis and data processing.
Results: Metabolic, hepatic and renal biomarkers, and hormonal values were also important (P < 0.05) between the patient group and the control group. The patients had high glucose, triglycerides, cholesterol, liver enzymes (ALT, AST and ALP) and kidney (urea, urate acid, creatinine and potassium) indicators. The patients experienced the reduction of albumin and erythropoietin. There was no significant difference between the total protein, sodium and calcium levels according to the group (p > 0.05.(
Conclusions: We found that physiological parameters are connected with the presence of renal dysfunction to a large extent. The chronic renal failure affects to a considerable extent the biochemical indicators and blood regulators, that is, the level of erythropoietin and ghrelin. The results indicate a lack of electrolyte, metabolism, and hormone homeostasis, which implies that ghrelin and erythropoietin are the possible diagnostic and treatment etiological variables in the treatment of renal diseases.
- renal failure
- erythropoietin,
- ghrelin,
- biochemical parameters
How to Cite
References
[1] Matsushita K, Ballew SH, Wang AY, Kalyesubula R, Schaeffner E, Agarwal R. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nature Reviews Nephrology. 2022 Nov;18(11):696-707. [LINK]
[2] Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. Jama. 2007 Nov 7;298(17):2038-47.
[Doi:10.1001/jama.298.17.2038]
[3] Martinusen D, Marin JG, Cheng E, Lau W. Chronic kidney disease and end stage renal disease. InRenal Medicine and Clinical Pharmacy 2020 Jul 9 (pp. 45-115). Cham: Springer International Publishing. [Doi:10.1007/978-3-030-37655-0_4]
[4] Peters F, Westphal C, Kramer A, Westerman R. is the rise in the Prevalence of renal replacement Therapy at Older ages the Price for living longer?. Frontiers in Public Health. 2018 May 4;6:138. doi: 10.3389/fpubh.2018.00138 [5] Rosique-Esteban N, Guasch-Ferré M, Hernández-Alonso P, Salas-Salvadó J. Dietary magnesium and cardiovascular disease: a review with emphasis in epidemiological studies. Nutrients. 2018 Feb 1;10(2):168. [Doi:10.3389/fpubh.2018.00138]
[5] Rosique-Esteban N, Guasch-Ferré M, Hernández-Alonso P, Salas-Salvadó J. Dietary magnesium and cardiovascular disease: a review with emphasis in epidemiological studies. Nutrients. 2018 Feb 1;10(2):168. [Doi:10.3390/nu10020168]
[6] Rajab WJ, Al-Kubaisi F, Ali AY. Evaluation of serum magnesium in obesity and overweight and normal weight. Egyptian Journal of Chemistry. 2022 Dec 1;65(132):255-62. [DOI: 10.21608/ejchem.2022.119956.5384]
[7] Reznikov KM, Gorbunova NS. Search of new pharmaceuticals on the basis of darbepoetin in the treatment of ischemic stroke (review of literature). pharmacology. 2017;3(1-P):125-36. [LINK]
[8] Suresh S, Rajvanshi PK, Noguchi CT. The many facets of erythropoietin physiologic and metabolic response. Frontiers in physiology. 2020 Jan 17;10:1534. [Doi:10.3389/fphys.2019.01534]
[9] Zhang Y, Zhu X, Huang X, Wei X, Zhao D, Jiang L, Zhao X, Du Y. Advances in understanding the effects of erythropoietin on renal fibrosis. Frontiers in medicine. 2020 Feb 21;7:47.
[Doi:10.3389/fmed.2020.00047]
[10] Boniecka I, Jeznach-Steinhagen A, Michalska W, Rymarz A, Szostak-Węgierek D, Niemczyk S. Nutritional status, selected nutrients intake and their relationship with the concentration of ghrelin and adiponectin in patients with diabetic nephropathy. Nutrients. 2021 Dec 10;13(12):4416. [Doi.org/10.3390/nu13124416]
[11] Mahmood IS, Sarhat ER. Effects of chronic renal failure and hemodialysis on serum levels of apelin and ghrelin. Biochemical & Cellular Archives. 2022 Apr 1;22(1). [LINK]
[12] Rashad NM, Sami MM, Kamal NM. Association of Plasma and mRNA Expression Levels of Ghrelin with Nutritional Status in Egyptian Patients with End-Stage Renal Disease on Regular Hemodialysis. The Egyptian Journal of Hospital Medicine. 2022 Jul 1;88(1):3878-84. [Doi.org/10.21608/EJHM.2022.252232]
[13] Vaziri ND. Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease. Clinical and experimental nephrology. 2014 Apr;18(2):265-8. [DOI 10.1007/s10157-013-0847-z]
[14] Bulbul MC, Dagel T, Afsar B, Ulusu NN, Kuwabara M, Covic A, Kanbay M. Disorders of lipid metabolism in chronic kidney disease. Blood purification. 2018 Apr 27;46(2):144-52. [Doi.org/10.1159/000488816]
[15] Pugliese G, Penno G, Natali A, Barutta F, Di Paolo S, Reboldi G, Gesualdo L, De Nicola L, Society ID. Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”. Nutrition, Metabolism and Cardiovascular Diseases. 2019 Nov 1;29(11):1127-50. [Doi.org/10.1016/j.numecd.2019.07.017]
[16]Thomas, M. C., & Cherney, D. Z. (2018). The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia, 61, 2098-2107. [DOI: 10.1007/s00125-018-4669-0]
[17]Cohen DE, Fisher EA. Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease. InSeminars in liver disease 2013 Nov (Vol. 33, No. 04, pp. 380-388). Thieme Medical Publishers. [Doi:10.1055/s-0033-1358519]
[18] Zhang J, Zhang R, Wang Y, Li H, Han Q, Wu Y, Wang T, Liu F. The level of serum albumin is associated with renal prognosis in patients with diabetic nephropathy. Journal of diabetes research. 2019;2019(1):7825804. [Doi.org/10.1155/2019/7825804]
[19] Gatta A, Verardo A, Bolognesi M. Hypoalbuminemia. Internal and emergency medicine. 2012 Oct;7(Suppl 3):193-9. [LINK]
[20] Iwasaki T, Togashi Y, Terauchi Y. Significant association of serum albumin with severity of retinopathy and neuropathy, in addition to that of nephropathy, in Japanese type 2 diabetic patients. Endocrine journal. 2008;55(2):311-6. [Doi.org/10.1507/endocrj.K07-086]
[21] Sette LH, de Almeida Lopes EP. Liver enzymes serum levels in patients with chronic kidney disease on hemodialysis: a comprehensive review. Clinics. 2014 Apr;69(4):271-8.
[Doi:10.6061/clinics/2014(04)09]
[22] Zong L, Wang X, Li Z, Zhao X, Liu L, Li H, Meng X, Wang Y, Wang Y. Alkaline phosphatase and outcomes in patients with preserved renal function: results from China National Stroke Registry. Stroke. 2018 May;49(5):1176-82. [Doi:10.1161/STROKEAHA.118.020237]
[23] Drechsler C, Verduijn M, Pilz S, Krediet RT, Dekker FW, Wanner C, Ketteler M, Boeschoten EW, Brandenburg V, NECOSAD Study Group. Bone alkaline phosphatase and mortality in dialysis patients. Clinical Journal of the American Society of Nephrology. 2011 Jul 1;6(7):1752-9. [DOI: 10.2215/CJN.10091110]
[24]Chen C, Yang L, Li H, Chen F, Chen C, Gao R, Lv XY, Tang J. Raman spectroscopy combined with multiple algorithms for analysis and rapid screening of chronic renal failure. Photodiagnosis and photodynamic therapy. 2020 Jun 1;30:101792. [Doi:10.1016/j.pdpdt.2020.101792]
[25] Ficheux A, Gayrard N, Szwarc I, Soullier S, Bismuth-Mondolfo J, Brunet P, Servel MF, Argilés Ã. Use of spent dialysate analysis to estimate blood levels of uraemic solutes without blood sampling: urea. Nephrology Dialysis Transplantation. 2010 Mar 1;25(3):873-9. [Doi:10.1093/ndt/gfp539]
[26] Dhondup T, Qian Q. Electrolyte and acid-base disorders in chronic kidney disease and end-stage kidney failure. Blood purification. 2017 Jan 24;43(1-3):179-88. [Doi:10.1159/000452725]
[27] He J, Mills KT, Appel LJ, Yang W, Chen J, Lee BT, Rosas SE, Porter A, Makos G, Weir MR, Hamm LL. Urinary sodium and potassium excretion and CKD progression. Journal of the American Society of Nephrology. 2016 Apr 1;27(4):1202-12. [DOI: 10.1681/ASN.2015010022]
[28] Panjeta M, Tahirović I, Sofić E, Ćorić J, Dervišević A. Interpretation of erythropoietin and haemoglobin levels in patients with various stages of chronic kidney disease. Journal of medical biochemistry. 2017 Apr 22;36(2):145. [Doi: 10.1515/jomb-2017-0014]
[29] Farsijani NM, Liu Q, Kobayashi H, Davidoff O, Sha F, Fandrey J, Ikizler TA, O’Connor PM, Haase VH. Renal epithelium regulates erythropoiesis via HIF-dependent suppression of erythropoietin. The Journal of clinical investigation. 2016 Apr 1;126(4):1425-37. [Doi:10.1172/JCI74997]
[30] Souma T, Yamazaki S, Moriguchi T, Suzuki N, Hirano I, Pan X, Minegishi N, Abe M, Kiyomoto H, Ito S, Yamamoto M. Plasticity of renal erythropoietin-producing cells governs fibrosis. Journal of the American Society of Nephrology. 2013 Oct 1;24(10):1599-616. [DOI: 10.1681/ASN.2013010030]
[31]Kobayashi H, Terao T, Tsushima T, Abe Y, Miura D, Narita K, Kitadate A, Takeuchi M, Matsue K. Association between serum erythropoietin levels and renal reversibility in patients with renal impairment from multiple myeloma. Cancer medicine. 2020 Jun;9(12):4460-6. [Doi:10.1002/cam4.3050]
[32] Fujita Y, Doi Y, Hamano T, Hatazaki M, Umayahara Y, Isaka Y, Tsubakihara Y. Low erythropoietin levels predict faster renal function decline in diabetic patients with anemia: a prospective cohort study. Scientific reports. 2019 Oct 16;9(1):14871. [Doi.org/10.1038/s41598-019-51207-8 ]
[33] Bunn RC, Cockrell GE, Ou Y, Thrailkill KM, Lumpkin Jr CK, Fowlkes JL. Palmitate and insulin synergistically induce IL-6 expression in human monocytes. Cardiovascular Diabetology. 2010 Nov 5;9(1):73. [LINK]
[34] Park SY, Lee JY, Tak WY, Kweon YO, Lee MS. Erythropoietin decreases carbon tetrachloride-induced hepatic fibrosis by inhibiting transforming growth factor-beta. Chinese medical journal. 2012 Sep 1;125(17):3098-103. [PMID]
[35]Tögel FE, Ahlstrom JD, Yang Y, Hu Z, Zhang P, Westenfelder C.Carbamylated erythropoietin outperforms erythropoietin in the treatment of AKI-on-CKD and other AKI models. Journal of the American Society of Nephrology. 2016 Nov 1;27(11):3394-404.
[DOI: 10.1681/ASN.2015091059]
[36] Canpolat N, Sever L, Agbas A, Tasdemir M, Oruc C, Ekmekci OB, Caliskan S. Leptin and ghrelin in chronic kidney disease: their associations with protein-energy wasting. Pediatric Nephrology. 2018 Nov;33(11):2113-22. [LINK]
[37]Boshra V, Abbas AM. Effects of peripherally and centrally applied ghrelin on the oxidative stress induced by renin angiotensin system in a rat model of renovascular hypertension. Journal of basic and clinical physiology and pharmacology. 2017 Jul 26;28(4):347-54. [Doi:10.1515/jbcpp-2016-0145]
[38] Sun GX, Ding R, Li M, Guo Y, Fan LP, Yue LS, Li LY, Zhao M. Ghrelin attenuates renal fibrosis and inflammation of obstructive nephropathy. The Journal of urology. 2015 Jun;193(6):2107-15. [Doi:10.1016/j.juro.2014.11.098]
- Abstract Viewed: 102 times
- PDF Downloaded: 82 times